Pre-clinical models with better translational value are important, given the pressing urge for a disease-modifying treatment for AD and other tauopathies, especially in the face of recent failures of Aβ and tau-targeting drugs in expensive and time-consuming later stage clinical trials [22]. This evidence concerns the gene MAPT and Alzheimer disease.